Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
66 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Degenerative Disc Disease - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Degenerative Disc Disease - Pipeline Review, H2 2014', provides an overview of the Degenerative Disc Disease's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Degenerative Disc Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Degenerative Disc Disease and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Degenerative Disc Disease - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Degenerative Disc Disease and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Degenerative Disc Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Degenerative Disc Disease pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Degenerative Disc Disease - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Degenerative Disc Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Degenerative Disc Disease Overview 7 Therapeutics Development 8 Pipeline Products for Degenerative Disc Disease - Overview 8 Pipeline Products for Degenerative Disc Disease - Comparative Analysis 9 Degenerative Disc Disease - Therapeutics under Development by Companies 10 Degenerative Disc Disease - Therapeutics under Investigation by Universities/Institutes 11 Degenerative Disc Disease - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Degenerative Disc Disease - Products under Development by Companies 15 Degenerative Disc Disease - Products under Investigation by Universities/Institutes 16 Degenerative Disc Disease - Companies Involved in Therapeutics Development 17 AnGes MG, Inc. 17 Bioheart, Inc. 18 Bone Therapeutics SA 19 DePuy Spine, Inc. 20 Discgenics, Inc 21 ISTO Technologies, Inc. 22 K-Stemcell Co., Ltd. 23 Mesoblast Limited 24 TissueGene, Inc. 25 Yuhan Corporation 26 Degenerative Disc Disease - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 AdipoCell - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ALLOB - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 brtxDISC - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 CHND-1 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 MPC-25-Osteo - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 NuQu Cell-Based Therapy - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Peptides to Antagonize IL-1 Receptor for Dermatology, Musculoskeletal and CNS Disorders - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Poly N-Acetyl Glucosamine Hydrogel - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Recombinant Protein for Degenerative Disc Disease - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 S-414114 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 Stem Cell Therapy - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Stem Cell Therapy for Degenerative Disc Disease - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 TG-D - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 YH-14618 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Degenerative Disc Disease - Recent Pipeline Updates 58 Degenerative Disc Disease - Product Development Milestones 63 Featured News & Press Releases 63 Sep 15, 2014: Bone Therapeutics receives clearance for ALLOB� phase II trial in spine fusion 63 Mar 26, 2014: Bioheart Announces Clinical Study for Degenerative Disc Disease 63 Appendix 65 Methodology 65 Coverage 65 Secondary Research 65 Primary Research 65 Expert Panel Validation 65 Contact Us 66 Disclaimer 66
List of Tables Number of Products under Development for Degenerative Disc Disease, H2 2014 8 Number of Products under Development for Degenerative Disc Disease - Comparative Analysis, H2 2014 9 Number of Products under Development by Companies, H2 2014 10 Number of Products under Investigation by Universities/Institutes, H2 2014 11 Comparative Analysis by Clinical Stage Development, H2 2014 12 Comparative Analysis by Early Stage Development, H2 2014 13 Comparative Analysis by Unknown Stage Development, H2 2014 14 Products under Development by Companies, H2 2014 15 Products under Investigation by Universities/Institutes, H2 2014 16 Degenerative Disc Disease - Pipeline by AnGes MG, Inc., H2 2014 17 Degenerative Disc Disease - Pipeline by Bioheart, Inc., H2 2014 18 Degenerative Disc Disease - Pipeline by Bone Therapeutics SA, H2 2014 19 Degenerative Disc Disease - Pipeline by DePuy Spine, Inc., H2 2014 20 Degenerative Disc Disease - Pipeline by Discgenics, Inc, H2 2014 21 Degenerative Disc Disease - Pipeline by ISTO Technologies, Inc., H2 2014 22 Degenerative Disc Disease - Pipeline by K-Stemcell Co., Ltd., H2 2014 23 Degenerative Disc Disease - Pipeline by Mesoblast Limited, H2 2014 24 Degenerative Disc Disease - Pipeline by TissueGene, Inc., H2 2014 25 Degenerative Disc Disease - Pipeline by Yuhan Corporation, H2 2014 26 Assessment by Monotherapy Products, H2 2014 27 Number of Products by Stage and Target, H2 2014 29 Number of Products by Stage and Mechanism of Action, H2 2014 31 Number of Products by Stage and Route of Administration, H2 2014 33 Number of Products by Stage and Molecule Type, H2 2014 35 Degenerative Disc Disease Therapeutics - Recent Pipeline Updates, H2 2014 58
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
